Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Boji Medical Technology Co., Ltd. (SHE: 300404), a Chinese clinical research organization (CRO), has entered into a technology transfer agreement with fellow domestic pharmaceutical company Chengdu Pusch Pharmaceutical Co., Ltd., transferring its fluconazole ear drops formulation for RMB 14 million (USD 2 million).

Transaction Details

The transferred asset represents a reformulation of the established antifungal agent fluconazole for targeted otic delivery, addressing a specialized segment of the anti-infective market with limited treatment options.

Strategic Context

For Boji Medical, the transaction aligns with its strategy of developing early-stage pharmaceutical assets and monetizing them through partnerships with specialized commercial-stage companies. As a CRO, this technology transfer represents an opportunity to generate revenue from its internal R&D capabilities beyond traditional contract research services.

For Chengdu Pusch, the acquisition provides immediate access to a late-preclinical stage asset in the anti-fungal space, potentially accelerating its pipeline development timeline and expanding its portfolio in specialized therapeutic areas.

External otitis affects millions of patients annually, with fungal etiology accounting for approximately 10% of cases. The targeted ear drop formulation aims to deliver effective therapy directly to the infection site while minimizing systemic exposure and associated side effects.

Forward-Looking Statements
This brief contains forward-looking statements regarding transaction completion and development timelines. Actual outcomes may differ based on regulatory decisions and market dynamics.-Fineline Info & Tech